Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

A double‐blind crossover study was conducted in four CYP2C19 genotype–defined metabolizer groups to assess whether increase in clopidogrel dosing can overcome reduced pharmacodynamic response in CYP2C19 poor metabolizers (PMs). Ten healthy subjects in each of four metabolizer groups were randomized...

Ausführliche Beschreibung